Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06344793
Status:
RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-28
Brief Title:
Initial CDK 46 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive HER2 Negative Unresectable or Metastatic Breast Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Multi-center Study of the Clinical Outcomes Between Initial CDK 46 Inhibitor Plus Endocrine Therapy and Initial Chemotherapy in HR Positive HER2 Negative Unresectable or Metastatic Breast Cancer in Real World Practice
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multi-center real world study to evaluate the clinical outcomes between initial CDK 46 Inhibitor plus endocrine therapy and initial chemotherapy in HR positive HER2 negative unresectable or metastatic breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None